DBV Technologies S.A. Logo

DBV Technologies S.A.

DBV.PA

(2.5)
Stock Price

0,62 EUR

-77.4% ROA

-131.16% ROE

-0.83x PER

Market Cap.

73.273.802,25 EUR

9.6% DER

0% Yield

-638.21% NPM

DBV Technologies S.A. Stock Analysis

DBV Technologies S.A. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

DBV Technologies S.A. Fundamental Stock Analysis
# Analysis Rating
1 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

2 PBV

With a remarkably low PBV ratio (-2.95x), the stock offers substantial upside potential at a bargain price.

3 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

4 Net Profit Growth

Over the last five years, this company's net profit has shown continuous growth, reflecting a robust financial performance and making it an attractive choice for potential investors.

5 Revenue Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

6 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

7 ROE

The stock's ROE indicates a negative return (-86.04%) on shareholders' equity, suggesting poor financial performance.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

DBV Technologies S.A. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

DBV Technologies S.A. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Sell
4 Stoch RSI Sell

DBV Technologies S.A. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

DBV Technologies S.A. Revenue
Year Revenue Growth
2011 163.373
2012 230.592 29.15%
2013 251.042 8.15%
2014 256.285 2.05%
2015 220.847 -16.05%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 5.708.000 100%
2022 4.800.000 -18.92%
2023 9.600.000 50%
2023 0 0%
2024 4.644.000 100%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

DBV Technologies S.A. Research and Development Expenses
Year Research and Development Expenses Growth
2011 8.652.546
2012 15.313.751 43.5%
2013 23.980.968 36.14%
2014 25.710.688 6.73%
2015 37.428.115 31.31%
2016 82.903.537 54.85%
2017 126.247.090 34.33%
2018 122.593.228 -2.98%
2019 113.694.103 -7.83%
2020 101.607.000 -11.9%
2021 70.336.000 -44.46%
2022 75.500.000 6.84%
2023 55.200.000 -36.78%
2023 68.337.742 19.22%
2024 101.496.000 32.67%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

DBV Technologies S.A. General and Administrative Expenses
Year General and Administrative Expenses Growth
2011 3.102.304
2012 6.108.163 49.21%
2013 8.712.958 29.9%
2014 9.871.180 11.73%
2015 18.352.174 46.21%
2016 36.624.458 49.89%
2017 42.487.463 13.8%
2018 45.387.783 6.39%
2019 49.157.630 7.67%
2020 34.140.000 -43.99%
2021 30.520.000 -11.86%
2022 24.300.000 -25.6%
2023 24.800.000 2.02%
2023 22.877.000 -8.41%
2024 28.812.000 20.6%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

DBV Technologies S.A. EBITDA
Year EBITDA Growth
2011 -9.109.009
2012 -16.802.780 45.79%
2013 -26.155.004 35.76%
2014 -28.446.486 8.06%
2015 -47.510.550 40.13%
2016 -119.015.818 60.08%
2017 -169.688.317 29.86%
2018 -186.316.632 8.92%
2019 -163.468.949 -13.98%
2020 -124.832.000 -30.95%
2021 -100.455.000 -24.27%
2022 -96.600.000 -3.99%
2023 -73.200.000 -31.97%
2023 -89.405.790 18.13%
2024 -125.664.000 28.85%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

DBV Technologies S.A. Gross Profit
Year Gross Profit Growth
2011 79.054
2012 120.880 34.6%
2013 109.688 -10.2%
2014 90.548 -21.14%
2015 80.905 -11.92%
2016 -1.349.000 106%
2017 -2.926.000 53.9%
2018 -4.212.000 30.53%
2019 -2.724.148 -54.62%
2020 -15.344.203 82.25%
2021 -3.565.415 -330.36%
2022 -15.499.259 77%
2023 9.600.000 261.45%
2023 4.159.592 -130.79%
2024 4.644.000 10.43%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

DBV Technologies S.A. Net Profit
Year Net Profit Growth
2011 -9.385.208
2012 -17.208.453 45.46%
2013 -26.659.692 35.45%
2014 -29.198.745 8.7%
2015 -48.842.193 40.22%
2016 -120.452.442 59.45%
2017 -177.187.657 32.02%
2018 -189.974.834 6.73%
2019 -172.042.746 -10.42%
2020 -159.559.000 -7.82%
2021 -97.809.000 -63.13%
2022 -96.300.000 -1.57%
2023 -66.800.000 -44.16%
2023 -67.269.401 0.7%
2024 -132.464.000 49.22%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

DBV Technologies S.A. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2011 -1
2012 -1 100%
2013 -2 0%
2014 -2 0%
2015 -2 50%
2016 -5 50%
2017 -7 42.86%
2018 -7 -16.67%
2019 -5 -50%
2020 -3 -100%
2021 -2 -100%
2022 -1 0%
2023 -1 0%
2023 -1 0%
2024 -1 100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

DBV Technologies S.A. Free Cashflow
Year Free Cashflow Growth
2011 -8.872.068
2012 -14.275.113 37.85%
2013 -19.918.393 28.33%
2014 -26.182.752 23.93%
2015 -34.188.660 23.42%
2016 -71.247.529 52.01%
2017 -146.194.544 51.27%
2018 -161.714.711 9.6%
2019 -149.564.253 -8.12%
2020 -168.368.000 11.17%
2021 -109.160.000 -54.24%
2022 -56.454.000 -93.36%
2023 -25.717.000 -119.52%
2023 -74.302.877 65.39%
2024 -35.805.000 -107.52%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

DBV Technologies S.A. Operating Cashflow
Year Operating Cashflow Growth
2011 -7.945.235
2012 -13.797.113 42.41%
2013 -18.300.996 24.61%
2014 -25.000.793 26.8%
2015 -29.260.053 14.56%
2016 -62.616.213 53.27%
2017 -137.142.789 54.34%
2018 -156.280.027 12.25%
2019 -143.963.393 -8.56%
2020 -165.607.000 13.07%
2021 -108.242.000 -53%
2022 -55.700.000 -94.33%
2023 -25.553.000 -117.98%
2023 -73.676.672 65.32%
2024 -35.073.000 -110.07%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

DBV Technologies S.A. Capital Expenditure
Year Capital Expenditure Growth
2011 926.833
2012 478.000 -93.9%
2013 1.617.398 70.45%
2014 1.181.959 -36.84%
2015 4.928.607 76.02%
2016 8.631.315 42.9%
2017 9.051.755 4.64%
2018 5.434.683 -66.56%
2019 5.600.860 2.97%
2020 2.761.000 -102.86%
2021 918.000 -200.76%
2022 754.000 -21.75%
2023 164.000 -359.76%
2023 626.205 73.81%
2024 732.000 14.45%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

DBV Technologies S.A. Equity
Year Equity Growth
2011 15.172.857
2012 51.806.722 70.71%
2013 55.779.897 7.12%
2014 140.382.507 60.27%
2015 352.127.566 60.13%
2016 255.403.643 -37.87%
2017 155.868.944 -63.86%
2018 138.739.418 -12.35%
2019 192.178.958 27.81%
2020 205.490.000 6.48%
2021 99.274.000 -106.99%
2022 194.500.000 48.96%
2023 -61.500.000 416.26%
2023 126.905.354 148.46%
2024 79.095.000 -60.45%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

DBV Technologies S.A. Assets
Year Assets Growth
2011 20.376.062
2012 56.834.471 64.15%
2013 63.846.018 10.98%
2014 152.506.823 58.14%
2015 375.309.951 59.37%
2016 302.364.225 -24.13%
2017 213.315.497 -41.75%
2018 196.464.195 -8.58%
2019 270.494.667 27.37%
2020 272.246.000 0.64%
2021 146.723.000 -85.55%
2022 246.500.000 40.48%
2023 -15.700.000 1670.06%
2023 165.650.658 109.48%
2024 114.190.000 -45.07%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

DBV Technologies S.A. Liabilities
Year Liabilities Growth
2011 5.203.205
2012 5.027.748 -3.49%
2013 8.066.121 37.67%
2014 12.124.315 33.47%
2015 23.182.384 47.7%
2016 46.959.530 50.63%
2017 57.446.553 18.26%
2018 57.724.776 0.48%
2019 78.314.589 26.29%
2020 66.755.000 -17.32%
2021 47.449.000 -40.69%
2022 52.000.000 8.75%
2023 0 0%
2023 38.745.303 100%
2024 35.095.000 -10.4%

DBV Technologies S.A. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.14
Net Income per Share
-0.92
Price to Earning Ratio
-0.83x
Price To Sales Ratio
5.29x
POCF Ratio
-0.71
PFCF Ratio
-0.69
Price to Book Ratio
0.93
EV to Sales
1.06
EV Over EBITDA
-0.17
EV to Operating CashFlow
-0.14
EV to FreeCashFlow
-0.14
Earnings Yield
-1.21
FreeCashFlow Yield
-1.44
Market Cap
0,07 Bil.
Enterprise Value
0,01 Bil.
Graham Number
4.12
Graham NetNet
0.48

Income Statement Metrics

Net Income per Share
-0.92
Income Quality
1.17
ROE
-1.31
Return On Assets
-0.77
Return On Capital Employed
-1.07
Net Income per EBT
1
EBT Per Ebit
0.95
Ebit per Revenue
-6.69
Effective Tax Rate
-0.04

Margins

Sales, General, & Administrative to Revenue
1.9
Research & Developement to Revenue
5.3
Stock Based Compensation to Revenue
0.44
Gross Profit Margin
1
Operating Profit Margin
-6.69
Pretax Profit Margin
-6.39
Net Profit Margin
-6.38

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.07
Free CashFlow per Share
-1.1
Capex to Operating CashFlow
-0.02
Capex to Revenue
0.18
Capex to Depreciation
-0.16
Return on Invested Capital
-1.11
Return on Tangible Assets
-0.77
Days Sales Outstanding
544.64
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0.67
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0.03

Balance Sheet

Cash per Share
0,69
Book Value per Share
0,82
Tangible Book Value per Share
0.82
Shareholders Equity per Share
0.82
Interest Debt per Share
0.08
Debt to Equity
0.1
Debt to Assets
0.07
Net Debt to EBITDA
0.68
Current Ratio
3.29
Tangible Asset Value
0,08 Bil.
Net Current Asset Value
0,05 Bil.
Invested Capital
81456000
Working Capital
0,06 Bil.
Intangibles to Total Assets
0
Average Receivables
0,02 Bil.
Average Payables
0,02 Bil.
Average Inventory
863500.5
Debt to Market Cap
0.1

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

DBV Technologies S.A. Dividends
Year Dividends Growth

DBV Technologies S.A. Profile

About DBV Technologies S.A.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

CEO
Mr. Daniel Tassé
Employee
106
Address
177-181 Avenue Pierre Brossolette
Montrouge, 92120

DBV Technologies S.A. Executives & BODs

DBV Technologies S.A. Executives & BODs
# Name Age
1 Mr. Edward P. Jordan M.B.A.
Senior Vice President of Commercial Operations North America
70
2 Katie Matthews
Investor Relations Officer
70
3 Dr. Pharis Mohideen
Chief Medical Officer
70
4 Ms. Michele F. Robertson
Chief Legal Officer
70
5 Ms. Caroline Daniere
Chief Human Resources Officer & Chief of Staff
70
6 Dr. Wence Agbotounou
Chief Clinical Trial Officer & Senior Vice President
70
7 Alan Kerr
Senior Vice President & Head of Global Regulatory Affairs
70
8 Dr. Kevin P. Malobisky M.S., Ph.D., R.A.C.
Chief Operations Officer
70
9 Ms. Virginie Simone Jeanine Verrechia Boucinha M.B.A.
Chief Financial Officer & Principal Accounting Officer
70
10 Mr. Daniel Tassé
Chief Executive Officer & Director
70

DBV Technologies S.A. Competitors

Genfit S.A. Logo
Genfit S.A.

GNFT.PA

(0.8)
Innate Pharma S.A. Logo
Innate Pharma S.A.

IPH.PA

(0.5)
Cellectis S.A. Logo
Cellectis S.A.

ALCLS.PA

(0.5)
ERYTECH Pharma S.A. Logo
ERYTECH Pharma S.A.

ERYP.PA

(1.5)
Nanobiotix S.A. Logo
Nanobiotix S.A.

NANO.PA

(1.8)